

Amendments to the Claims

Claim 1 (Cancelled)

Claim 2 (Currently amended): A method of inhibiting an antigen-specific response of a T cell to subsequent presentation of said antigen, comprising administering to said T cell an effective amount of exogenous interleukin-10 and said antigen *in vitro*.

Claim 3 (Previously presented): The method of Claim 2:

- a) wherein said T cell response is mediated by a macrophage, APC, langerhans cell, or dendritic cell;
- b) further inhibiting proliferative response of CD4+ host-reactive T cell clones;

or

- c) wherein said inhibiting persists for at least about 21 days.

Claim 4 (Original): The method of Claim 2, wherein said effective amount is sufficient to decrease responder T cell activation.

Claim 5 (Previously presented): The method of Claim 4, further comprising reduced T cell-stimulatory capacity of peripheral blood mononuclear cells, dendritic cells, monocytes, and/or normal B cells.

Claims 6-14 (Cancelled)

Claim 15 (Currently amended): A method of suppressing a T cell response to an antigen. comprising administering to said T cell *in vitro* a combination of:

- a) IL-10; and
- b) either said antigen or anti-CD3 antibodies.

6  
Claim 10 (Original): The method of Claim 15, wherein said antigen is alloantigen or self antigen.

7  
Claim 17 (Original): The method of Claim 16, wherein said antigen is restricted by MHC molecules.

Claim 18 (Canceled)

8  
Claim 19 (Previously presented) The method of Claim 15, which further comprising suppressing a T cell response to subsequent stimulation to said antigen.

9  
Claim 20 (Previously presented): The method of Claim 19, wherein said response to subsequent stimulation accompanies tissue transplantation.

10  
Claim 21 (Original): The method of Claim 20, wherein said tissue is an organ or bone marrow.

11  
Claim 22 (Original): The method of Claim 20, wherein said T cell is from the recipient of said tissue transplantation.

12  
Claim 23 (Currently amended): The method of Claim 15, wherein said response accompanies tissue transplantation and:

- a) said administering is prior to said tissue transplantation;
- b) said T-cell is introduced to the recipient of said tissue transplantation; or
- c) IL-10 is administered to the tissue to be transplanted before said transplantation.

13

Claim 24 (Original): The method of Claim 16, wherein said antigen causes an autoimmune disease.

6

14

Claim 25 (Currently amended): A method of suppressing a subsequent response of a T cell to an antigen, comprising administering to a T cell in vitro a combination of:

- a) exogenous IL-10; and
- b) either antigen or anti-CD3 antibodies.

15

Claim 26 (Original): The method of Claim 25, wherein said IL-10 is administered for at least about 7 days.

14

16

Claim 27 (Currently amended): A method of inducing in T-cell anergy to an MHC antigen in a T cell, comprising administering to a precursor of said T cell precursor in vitro:

- a) exogenous IL-10 and said antigen; or
- b) exogenous IL-10 and an anti-CD3 antibody.

Claims 28-30 (Cancelled)